MedTrace Logo

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

NCT02660944 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-03-10

Study results available
· View outcomes & findings →

Summary

This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.

Conditions

Interventions

DRUG

RSLV-132

RNase-Fc fusion protein

DRUG

Placebo

Saline placebo

Sponsors & Collaborators

  • Resolve Therapeutics

    lead INDUSTRY

Principal Investigators

  • James Posada, Ph.D. · Resolve Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-03
Primary Completion
2020-05-28
Completion
2020-08-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660944 on ClinicalTrials.gov